Anusha Abdullah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anusha Abdullah has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ina Dewenter
Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, LMU University Hospital, Ludwig-Maximilians-Universität München, Lindwurmstraße 2a, 80337 Munich, Germany
2 shared publications - Katharina Theresa Obermeier
Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, LMU University Hospital, Ludwig-Maximilians-Universität München, Lindwurmstraße 2a, 80337 Munich, Germany
2 shared publications - Sven Otto
Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Lindwurmstrasse 2a, 80337 Munich, Germany
2 shared publications - Wenko Smolka
Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, LMU University Hospital, Ludwig-Maximilians-Universität München, Lindwurmstraße 2a, 80337 Munich, Germany
2 shared publications - David Steybe
Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Munich, Germany
1 shared publication - Eric Hesse
Institute of Musculoskeletal Medicine, Musculoskeletal University Center Munich, University Hospital, LMU Munich, Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 7 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7546
X-Linked Hypophosphatemia: Does Targeted Therapy Modify Dental Impairment?
X-linked hypophosphatemia is a rare, hereditary disorder that significant influences teeth and alveolar bone. The first clinical sign leading to the diagnosis of X-linked hypophosphatemia is often dental impairment with dental abscesses and dentin mineralization defects. Genetic analysis helped find the responsible gene and therefore opened up new ways of therapeutically managing X-linked hypophosphatemia. The human monoclonal antibody Burosumab represents a milestone in the targeted therapy of this hereditary disease by directly addressing its pathophysiology. Targeted therapy has been shown to improve skeletal impairment, pain, and phosphate metabolism. However, the influence of this new therapy on dental impairment has only been addressed in a few recent studies with varying results. Therefore, in this review, we aim to summarize the dental phenotype and analyze the different treatment modalities with a focus on dental impairment.
- 7 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7546
Open AccessX-Linked Hypophosphatemia: Does Targeted Therapy Modify Dental Impairment?
X-linked hypophosphatemia is a rare, hereditary disorder that significant influences teeth and alveolar bone. The first clinical sign leading to the diagnosis of X-linked hypophosphatemia is often dental impairment with dental abscesses and dentin mineralization defects. Genetic analysis helped find the responsible gene and therefore opened up new ways of therapeutically managing X-linked hypophosphatemia. The human monoclonal antibody Burosumab represents a milestone in the targeted therapy of this hereditary disease by directly addressing its pathophysiology. Targeted therapy has been shown to improve skeletal impairment, pain, and phosphate metabolism. However, the influence of this new therapy on dental impairment has only been addressed in a few recent studies with varying results. Therefore, in this review, we aim to summarize the dental phenotype and analyze the different treatment modalities with a focus on dental impairment.
- Open Access
- 17 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (12) , 4100
Fibrous Dysplasia of the Jaw: Advances in Imaging and Treatment
A total of 7% of all benign bone lesions are diagnosed as fibrous dysplasia (FD). The symptoms of FD of the jaw range from asymptomatic to dental anomalies, pain and facial asymmetry. Due to its resemblance to other fibro-osseous bone lesions, misdiagnosis often occurs and can lead to inadequate treatment. Particularly in the jaw, this lesion does not become quiescent during puberty, making fundamental knowledge about the diagnosis and treatment of FD crucial. Mutational analysis and nonsurgical approaches offer new diagnostic and therapeutic options. In this review, we examine the advances and the difficulties of the diagnosis and the various treatment modalities of FD of the jaw in order to capture the current scientific knowledge on this bone disease.
- 17 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (12) , 4100
Open AccessFibrous Dysplasia of the Jaw: Advances in Imaging and Treatment
A total of 7% of all benign bone lesions are diagnosed as fibrous dysplasia (FD). The symptoms of FD of the jaw range from asymptomatic to dental anomalies, pain and facial asymmetry. Due to its resemblance to other fibro-osseous bone lesions, misdiagnosis often occurs and can lead to inadequate treatment. Particularly in the jaw, this lesion does not become quiescent during puberty, making fundamental knowledge about the diagnosis and treatment of FD crucial. Mutational analysis and nonsurgical approaches offer new diagnostic and therapeutic options. In this review, we examine the advances and the difficulties of the diagnosis and the various treatment modalities of FD of the jaw in order to capture the current scientific knowledge on this bone disease.